Thank you for your interest in the IMPACT study. If you are a treating clinician, sign up and get involved in this exciting pharmacogenetics study.

Slide background Slide background
Slide background
First ever Pharmacogenetic testing in primary care
User-friendly report for physicians
Patients may experience faster response with fewer side effects
Slide background
Thornhill Medical Centre

became the first family practice clinic in Canada to offer genetic

testing to see how patients will respond to psychiatric medication.

Watch the Video

6500 Participants!

6500 Participants!

The IMPACT Study has recruited

over 6500 Participants!

Recently Started or Switching Medication?

Find out how you can participate in this study! Click Here to Participate

and still counting...

About The Study

Are you having difficulty finding the right medication(s) for your symptoms of?

  • Anxiety?
  • Depression?
  • Psychosis?
  • Impulse Control?

The IMPACT Study uses genetic testing (a saliva sample) to identify genetic variants that can influence how you may:

  1. respond to various psychiatric medications
  2. experience side effects from various psychiatric medications

Interested in Participating?

Please answer the following questions to see if you are eligible:

  • Is your doctor considering prescribing NEW psychiatric medication including treatment for anxiety, depression, psychosis, bipolar disorder, tic disorder, ADHD, sleep disorders and/or pain?
  • Are you 7 - 15 years of age?
    Are you 16 years of age or older?

What does genetic testing tell us?

Genetic testing of your liver enzymes and other genes will give an idea of how quickly you will break down some antidepressant and antipsychotic medications, whether you might need a different dose than most people, and your likelihood of getting some side effects.

GeneSight Testing

Beginning on November 10, 2014, patients enrolled in the IMPACT study will have their genes tested using Assurex Health proprietary technology, GeneSight® Psychotropic.

The switch to GeneSight testing is a result of the CAMH-Assurex Health partnership agreement. The goal of this agreement is to bring the benefits of a personalized approach to psychiatric treatment to more Canadians. Click here to learn more about the partnership.

The GeneSight® Psychotropic test analyzes how eight genes may affect a patient’s metabolism and their response to 33 antidepressant and antipsychotic medications approved by Health Canada. The expanded GeneSight report includes information on the same genes, antidepressant and antipsychotic medications that were available on the CAMH Pharmacogenetics report.

If you would like more details on the GeneSight® Psychotropic test, or to learn how you can register to receive the GeneSight® Psychotropic reports for your IMPACT patients, please contact the Assurex Health IMPACT Team at or We look forward to hearing from you!

CAMH and Assurex Health launch joint venture to advance personalized medicine in Canada

TORONTO – November 19, 2013 – The Centre for Addiction and Mental Health (CAMH), Canada’s leading hospital for mental health, and Assurex Health, a global leader in personalized medicine, have signed an agreement for a joint venture to bring the benefits of this treatment approach to more Canadians. The personalized approach helps to match the right medication at the right dose for each patient, based on their genetic makeup. Using Assurex Health’s GeneSight panel, physicians can easily see which psychiatric medications are likely to be effective for each patient and which ones are not, often avoiding treatment failure and side effects. CAMH

Get in Touch

Centre for Addiction and Mental Health
250 College Street
Toronto, Ontario
M5T 1R8
(416) 535-8501 Ext. 30240
1 (800) 928-3316
(416) 979-4666